Literature DB >> 1964157

In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus.

Y Obana1, T Nishino.   

Abstract

The antibacterial activities of sulbactam and YTR830H, both beta-lactamase inhibitors, were studied against Acinetobacter calcoaceticus, in vitro and in vivo. In-vitro susceptibility tests showed both to be very active against 80 clinical isolates of A. calcoaceticus. Against an intraperitioneal infection in mice, caused by A. calcoaceticus Ac54, the 50% effective doses of sulbactam and YTR830H were 1.62 and 16.7 mg/kg, respectively. Against A. calcoaceticus S31, a strain resistant to gentamicin, sulbactam and YTR830H were active both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964157     DOI: 10.1093/jac/26.5.677

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.

Authors:  M A Visalli; M R Jacobs; T D Moore; F A Renzi; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

3.  Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.

Authors:  Jun Yong Choi; Chang Oh Kim; Yoon Seon Park; Hee Jung Yoon; So Youn Shin; Young Keun Kim; Myung Soo Kim; Yeon-A Kim; Young Goo Song; Dongeun Yong; Kyungwon Lee; June Myung Kim
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

Review 4.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 5.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

6.  Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.

Authors:  Qiang Wang; Yuanxing Wu; Biyao Chen; Jianxin Zhou
Journal:  BMC Anesthesiol       Date:  2015-03-13       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.